Evidence map›Paper›PMID 42026330›Full record

ArticleEuropean radiology2026

Reference tissue uptake of [18F]PSMA-1007 in positron emission tomography of recurrent prostate cancer.

Bendik Skarre Abrahamsen, Ingerid Skjei Knudtsen, Andreas Julius Tulipan, Eivor Hernes, Trond Velde Bogsrud, Kirsten Margrete Selnæs, Håkon Johansen, Tone Frost Bathen, Mattijs Elschot

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bendik Skarre AbrahamsenDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.
Ingerid Skjei KnudtsenDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway. ingerid.s.knudtsen@ntnu.no.ORCID http://orcid.org/0000-0001-9313-2878
Andreas Julius TulipanNuclear Medicine/PET center, Department of Radiology, Haukeland University Hospital, Bergen, Norway.
Eivor HernesDivision of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Trond Velde BogsrudDivision of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Kirsten Margrete SelnæsDepartment of Radiology and Nuclear Medicine, Trondheim University Hospital-St. Olavs Hospital, Trondheim, Norway.
Håkon JohansenDepartment of Radiology and Nuclear Medicine, Trondheim University Hospital-St. Olavs Hospital, Trondheim, Norway.
Tone Frost Bathen *Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.
Mattijs Elschot *Research Department, Trondheim University Hospital-St. Olavs Hospital, Trondheim, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSemi-quantitative uptake measurements are part of the PROMISE framework for PET/CT interpretation of tracers targeting the prostate-specific membrane antigen (PSMA), where tumor uptake is compared to uptake in reference tissues. [18F]PSMA-1007 has primarily hepatobiliary excretion and it is suggested to use spleen as reference tissue instead of liver. The aim of this study is to investigate the normal range and interpatient variability of [18F]PSMA-1007 uptake in reference tissue for prostate cancer patients, with particular focus on the splenic uptake. MATERIALS AND

methodsA total of 102 [18F]PSMA-1007 PET/CT scans of prostate cancer patients with biochemical recurrence (BCR) from three hospitals were included in the analysis. SUV

resultsFor 15/102 (15%) and 20/102 (20%) of the patients, the SUV

conclusionIn this multicenter cohort of BCR patients, [18F]PSMA-1007 reference tissue uptake is reported in accordance with the PROMISE protocol. A substantial number of patients present with higher uptake in the spleen than in parotid glands, for reasons that are currently unexplained. Care should be taken when interpreting these values until further studies are conducted. KEY POINTS: Question The normal range for [18F]PSMA-1007 uptake values in PROMISE reference tissues are not well documented, challenging standardized lesion categorization in prostate cancer PET interpretation. Findings In a multicenter cohort, splenic [18F]PSMA-1007 uptake exceeded parotid gland uptake in a notable subgroup (15%), leading to situations where PSMA expression scoring according to the PROMISE framework cannot be applied as intended. Clinical relevance Unexpectedly high splenic uptake relative to parotid gland uptake of [18F]PSMA-1007 in some patients may affect lesion categorization; careful interpretation is advised.

Indexed as

Neoplasm Recurrence, LocalNiacinamideOligopeptidesPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAged, 80 and overFluorine RadioisotopesHumansMaleMiddle AgedRadiopharmaceuticalsReference ValuesSpleenTissue DistributionFluorine RadioisotopesNiacinamideOligopeptidesPSMA-1007RadiopharmaceuticalsPositron-emission tomographyProstatatic neoplasmsProstate-specific membrane antigenReference standardsSpleen

Identifiers

PMID42026330
PMCPMC13342144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.